BioArctic´s mission is to provide new and effective treatments for patients with disorders in the Central Nervous System. The company has evolved in a very positive way since its founding in 2003.
Our focus areas are Alzheimer´s disease, Parkinson´s disease, Spinal Cord Injury and other protein misfolding disorders. Our most advanced program is BAN2401, a monoclonal antibody targeting the toxic protofibrils of Abeta. Eisai and BioArctic are working together with our AD projects in a successful collaboration. BAN2401 is currently in Phase IIB in early AD patients. A study with up to 800 patients is ongoing in the US and starting in Europe during the spring of 2014.
We are preparing for the future of the company and have moved to new premises at Warfvinges väg 35, Stockholm.
Gunilla Osswald has been appointed our new CEO. She joined BioArctic in Feb 2013 as Deputy CEO and was recruited from AstraZeneca where she was VP for Neurodegenerative disorder projects. She has vast experience in leadership and drug development in neuroscience.
Pär Gellerfors, founder and previous CEO, will continue to work as an Executive Senior Advisor focusing on business development, external collaborations and our Spinal Cord Project.
Lars Lannfelt, founder and chairman, BioArctic Neuroscience AB